Working… Menu
Trial record 1 of 7 for:    circadin | alzheimer
Previous Study | Return to List | Next Study

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00940589
Recruitment Status : Completed
First Posted : July 16, 2009
Results First Posted : June 1, 2018
Last Update Posted : June 1, 2018
Information provided by (Responsible Party):
Neurim Pharmaceuticals Ltd.

Brief Summary:
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor. The effects of add-on Circadin® 2mg vs. placebo on the decline in cognitive skills and global functioning, as well as on daytime somnolence and will be assessed.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Sleep Disorder Drug: Circadin Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Study Start Date : September 2009
Actual Primary Completion Date : February 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

Arm Intervention/treatment
Experimental: Circadin
Drug: Circadin
Prolonged Release melatonin (Circadin) 2mg tablets

Placebo Comparator: Placebo
Drug: Placebo
Matched placebo tablets, with identical features to the Circadin tablets

Primary Outcome Measures :
  1. Change From Baseline to 24 Weeks in ADAS-cog [ Time Frame: 24 weeks ]
    ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a cognitive testing instrument used in clinical trials. It consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities that are often referred to as the core symptoms of AD. The test comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline. ADAS-cog was measured at base line and at end of treatment after 24 weeks.

Secondary Outcome Measures :
  1. Change From Baseline to 24 Weeks in iADL [ Time Frame: 24 weeks ]
    Instrumental Activities of Daily Living (iADL). The scale rates activities that represent key life tasks that people need to manage. These tasks are valuable for evaluating persons with early-stage disease, both to assess the level of disease and to determine the person's ability to care for himself or herself. Scores of 0 or 1 are given to every task (Bathing, Dressing, Tolieting, transferring, Continence and Feeding) to a total score of 6. , while 0 represents a patient who is very dependent and 6 represents patient who is independent. iADL was measured at base line and at end of treatment after 24 weeks.

  2. Change From Baseline to 24 Weeks in MMSE [ Time Frame: 24 weeks ]
    The Mini Mental State Examination (MMSE) is a brief assessment instrument used to assess cognitive function in elderly patients. The MMSE can be used to screen for cognitive impairment and as a measurement of cognition over time and with pharmacologic treatment. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention: the maximum score is 21. The second section tests the ability of the patient to name objects, follow verbal and written commands, write a sentence, and copy figures: the maximum score is 9. The scoring range for the MMSE is 0-30. Higher score represents better performance. MMSE was measured at base line and at end of treatment after 24 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent as dictated by local legal circumstances.
  2. Age range: adult patients between 50-85 years of age.
  3. Gender: men and women. Women of child bearing potential or within two years of the menopause must have a negative urine pregnancy test at the Screening Visit.
  4. A documented history of confirmed Alzheimer's disease
  5. Dementia severity: MMSE score > 15,
  6. Stable AChE inhibitor dose for 2 months prior to Screening visit.
  7. Stable medications for non-excluded concurrent medical conditions for four weeks prior to the screening visit.
  8. Stable doses of B12 and/or Folic acid supplements for at least 3 months prior to enrollment and throughout the study.
  9. Cranial image: no evidence of focal disease to account for dementia (established by CT, PET or MRI). If there is no such available scan (CT, PET or MRI), one must be performed prior to enrollment.
  10. Health: Physically acceptable for the study with no pathology likely to occur during or immediately after the study, as confirmed by medical history and exam and ECG.
  11. Clinical laboratory values must be within normal limits, or judged not clinically significant by the investigator.
  12. Residence: Stable home situation with no planned move during the 28-week investigational period.
  13. A family member or a regular caregiver that will be available for visits and will ensure compliance. The caregiver must speak fluent Hebrew, Russian or English.
  14. Ability to ingest oral medication and participate in all scheduled evaluations.
  15. Ability to spend 2 daily hours outdoors exposed to sunlight.

Exclusion Criteria:

  1. Severe agitation.
  2. Unstable medical condition, mental retardation.
  3. moderate to severe depression as defined by DSM-IV
  4. Use of benzodiazepines or other hypnotics during the study and the preceding four weeks.
  5. Use of Circadin® during the two weeks prior to study enrollment.
  6. Pharmacological immunosuppression.
  7. Participation in a clinical trial with any investigational agent within two months prior to study enrollment.
  8. Alcoholism.
  9. Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists.
  10. Patients with rare hereditary problems of galactose intolerance, the LAPP lactose deficiency or glucose mal absorption.
  11. Renal Failure with creatinine >150 micromol/l.
  12. Hepatic Failure with ASAT; ALAT; GGT levels above three times the upper normal limit.
  13. Clinically significant abnormal laboratory findings which have not been approved by the Safety Officer (sponsor)
  14. Other serious diseases that could interfere with patient assessment.
  15. Caregivers who are unwilling or unable to give informed consent or otherwise fulfill requirements of the study.
  16. Untreated B12 and/or Folic acid deficiency.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00940589

Layout table for location information
United States, Florida
Meridien Research
Brooksville, Florida, United States, 34601
Meridien Research
Saint Petersburg, Florida, United States, 33709
United States, New Jersey
Exodon LLC
Mount Arlington, New Jersey, United States, 07856
United States, Pennsylvania
Scranton Medical Institute
Scranton, Pennsylvania, United States, 18503
Merchav clinics
Tel-Aviv, Israel
United Kingdom
CPS Research
Glasgow, United Kingdom, G20 0XA
Sponsors and Collaborators
Neurim Pharmaceuticals Ltd.
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Neurim Pharmaceuticals Ltd. Identifier: NCT00940589    
Other Study ID Numbers: NEU AZ1
First Posted: July 16, 2009    Key Record Dates
Results First Posted: June 1, 2018
Last Update Posted: June 1, 2018
Last Verified: May 2018
Keywords provided by Neurim Pharmaceuticals Ltd.:
Alzheimer's Disease
Acetylcholinesterase inhibitor
cognitive function
Sleep disturbances
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Sleep Wake Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants